| Name | Brilaroxazine Hydrochloride |
|---|---|
| Synonyms |
6-{4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy}-2H-1,4-benzoxazin-3(4H)-one hydrochloride (1:1)
2H-1,4-Benzoxazin-3(4H)-one, 6-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-, hydrochloride (1:1) Brilaroxazine Hydrochloride |
| Description | PCC0104005 (PCC-0104005) is a novel modulator of serotonin, dopamine, and noradrenaline receptors, including partial agonism at dopamine D2, D3, D4, serotonin 5-HT1A, and 5-HT2A receptors and antagonism at 5-HT2B, 5-HT6, and 5-HT7 receptors; binds to D2, D3 and D4 with Ki of 0.11, 0.14 and 24 nM, 5-HT2A and 5-HT2B with Ki of 5.1 and 0.34 nM; inhibits 5-HTP-induced head twitches in rats, significantly reduces the escape latency of rats and improved the MK-801-induced memory impairment, improves the recognition disorder induced by MK-801, does not produce catalepsy in mice. |
|---|---|
| References | References 1. Xu Y, et al. Sci Rep. 2018 May 2;8(1):6892. View Related Products by Target Dopamine Receptor |
| Molecular Formula | C22H26Cl3N3O3 |
|---|---|
| Molecular Weight | 486.819 |
| Exact Mass | 485.103973 |